TEMBEXA
Total Payments
$1.3M
Transactions
18
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $181,425 | 13 | 1 |
| 2023 | $1.1M | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 18 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EBS-BCV-001 | Emergent BioSolutions Inc. | $1.1M | 0 |
| Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | Emergent BioSolutions Inc. | $181,425 | 1 |
Top Doctors Receiving Payments for TEMBEXA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Overland Park, KS | $1.2M | 7 |
| , M.D | Pediatrics | Madera, CA | $80,850 | 11 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 1
- Transactions 18
About TEMBEXA
TEMBEXA is a drug associated with $1.3M in payments to 1 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is Emergent BioSolutions Inc..
Payment data is available from 2023 to 2024. In 2024, $181,425 was paid across 13 transactions to 1 doctors.
The most common payment nature for TEMBEXA is "Unspecified" ($1.3M, 100.0% of total).
TEMBEXA is associated with 2 research studies, including "EBS-BCV-001" ($1.1M).